Acumen Pharmaceuticals (ABOS) Stock Price, Quote, News & History | Benzinga

Acumen Pharmaceuticals Inc (ABOS) Stock Price, Quote, News & History

ABOSNASDAQ

Trade with Public

Trade with Public

$2.90

-0.13-4.46%

Last update: Aug 28, 2:21 PM

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.02

Close

-

Volume / Avg.

246.03K / 463.49K

Day Range

$2.89 - $3.02

52 Wk Range

1.21 - 3.60

Market Cap

$209.36M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

6.39%

Days to Cover

10.4

Recent Acumen Pharmaceuticals Inc News

Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

Halozyme's ENHANZE Product Gets New Patent Grant in EU

Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which is produced using the company's proprietary ENHANZE manufacturing methods.

Zacks

Partner Content

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™ cellular drug in the next 3 to 4 months.

$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying

Although US stocks closed higher on Tuesday, there were a few notable insider trades.

Lisa Levin

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-91.79M

Investing Cash Flow (TTM)

78.95M

Financing Cash Flow (TTM)

35.47M

Free Cash Flow (TTM)

-91.79M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

22.63M

Analyst Trends and Forecast

2

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$140.93M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

3.83

Earnings Yield % (TTM)

-54.04%

Earnings Yield % (FWD)

-

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.79

Company Debt

Total Debt

$31.57M

LT Debt

$11.90M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$59.44M

Debt to Equity

0.55

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.02

Close

-

Volume / Avg.

246.03K / 463.49K

Day Range

$2.89 - $3.02

52 Wk Range

1.21 - 3.60

Market Cap

$209.36M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

59

Short Interest

6.39%

Days to Cover

10.4

About

Sector

Health Care

Industry

Biotechnology

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Acumen Pharmaceuticals (ABOS) stock?

A

You can purchase shares of Acumen Pharmaceuticals (NASDAQ:ABOS) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Acumen Pharmaceuticals (ABOS) competitors?

A

Other companies in Acumen Pharmaceuticals’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Acumen Pharmaceuticals (ABOS) stock?

A

Acumen Pharmaceuticals has a consensus price target of $7.14.

Q

What is the current price for Acumen Pharmaceuticals (ABOS)?

A

The stock price for Acumen Pharmaceuticals (NASDAQ: ABOS) is $2.895 last updated August 28, 2026 at 2:21 PM EDT.

Q

Does Acumen Pharmaceuticals (ABOS) pay a dividend?

A

There are no upcoming dividends for Acumen Pharmaceuticals.

Q

When is Acumen Pharmaceuticals (NASDAQ:ABOS) reporting earnings?

A

Acumen Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Acumen Pharmaceuticals (ABOS) going to split?

A

There is no upcoming split for Acumen Pharmaceuticals.

Q

What sector and industry does Acumen Pharmaceuticals (ABOS) operate in?

A

Acumen Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.